a novel drug for prevention and treatment peripheral neuropathy symptoms

Informazioni relative al progetto

MP-101

ID dell’accordo di sovvenzione: 854931

DOI

10.3030/854931

Progetto chiuso

Data della firma CE 31 Gennaio 2019

Data di avvio 1 Gennaio 2019

Data di completamento 30 Aprile 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

METYS PHARMACEUTICALS AG
Switzerland

Periodic Reporting for period 1 - MP-101 (a novel drug for prevention and treatment peripheral neuropathy symptoms)

Periodo di rendicontazione: 2019-01-01 al 2019-04-30

Sintesi del contesto e degli obiettivi generali del progetto

There were over 18 million new cases of cancer worldwide in 2018, out of which about 3.7 million were in Europe. Up to 40% of all cancer patients develop chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a condition that affects the peripheral nervous system, leading to long-lasting, painful, and difficult-to-treat symptoms. At present, only a few therapies are available for the treatment of peripheral neuropathy with moderately effectiveness, but none is specifically developed for CIPN and with substantial side effects for patients. Metys Pharmaceuticals Ltd. has developed MP-101 - a novel, non-sedating, painkiller for prevention and for treatment of CIPN-associated neuropathic pain.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

From 1 January until 30 April 2019, Metys Pharmaceuticals Ltd. used Phase 1 funding to carry out an extensive study with the objective to identify the technical and business requirements of delivering a finished and legally approved commercial version of MP-101. From a technical point of view, Metys reviewed in detail the current stage of MP-101 and defined a sound development plan for its approval and commercialisation. From a business point of view, the Company performed a deep market analysis, verified its business model and established a sound go-to-market strategy.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Metys’ novel drug aims at a clinical application in response to yet unanswered medical needs of cancer chemotherapy-induced peripheral neuropathy symptoms. So far, in fact there has been very limited progress in discovery of agents that show benefit in the treatment of CIPN. MP-101 has potential to become the first drug approved for the prevention and management of CIPN.

peripheral neutopathy